NR 605 EXAM 3 2026/2027-EDITION
REAL EXAM QUESTIONS AND 100% VERIFIED
ANSWERS + RATIONALE
Advanced Psychopharmacology & Mental Health - Comprehensive Review Edition
OVERVIEW: This 2026 practice exam is designed to mirror the structure and difficulty of
Chamberlain NR 605 Exam 3. It covers Major Depressive Disorder, Bipolar Disorders, Anxiety
Disorders, Schizophrenia Spectrum, Substance Use Disorders, Neurocognitive Disorders,
Psychopharmacology Principles, and Emergency Psychiatry.
All correct answes are highlight with green and Rationale After.
Total Questions: 138 | Time Suggestion: 3 hours | Passing Target: 100%+
1. Which adverse effect must be monitored when prescribing Lithium for
Psychopharmacology?
A. No monitoring needed
B. Increased hair growth
C. Increased creatinine and hypothyroidism
D. Weight loss only
Rationale: Lithium affects kidneys and thyroid, requires regular BMP and TSH. This aligns with DSM-5-TR
criteria and current psychopharmacology guidelines for Psychopharmacology.
2. Which adverse effect must be monitored when prescribing Sertraline for Emergency
Psychiatry?
A. Weight loss only
B. Increased hair growth
C. GI upset and SIADH/hyponatremia
D. No monitoring needed
Rationale: SSRIs can cause nausea and hyponatremia especially in elderly. This aligns with DSM-5-TR
criteria and current psychopharmacology guidelines for Emergency Psychiatry.
3. How long should a patient continue antidepressant therapy after remission of Bipolar I & II?
A. Stop immediately when feeling better
B. 3 days
C. 2 weeks
D. 6-12 months minimum for first episode
, Rationale: Continuation phase prevents relapse; first episode requires 6-12 months. This aligns with
DSM-5-TR criteria and current psychopharmacology guidelines for Bipolar I & II.
4. Which lab finding is associated with chronic use of Clozapine?
A. No labs affected
B. Decreased shoe size
C. Agranulocytosis and metabolic syndrome
D. Increased height
Rationale: Clozapine requires ANC monitoring and metabolic screening. This aligns with DSM-5-TR criteria
and current psychopharmacology guidelines for Emergency Psychiatry.
5. Which lab finding is associated with chronic use of Valproate?
A. Increased height
B. Decreased shoe size
C. Elevated LFTs and thrombocytopenia
D. No labs affected
Rationale: Valproate can cause hepatotoxicity and low platelets. This aligns with DSM-5-TR criteria and
current psychopharmacology guidelines for Emergency Psychiatry.
6. Which adverse effect must be monitored when prescribing Olanzapine for Bipolar I & II?
A. Weight gain and hyperglycemia
B. No monitoring needed
C. Weight loss only
D. Increased hair growth
Rationale: Second-gen antipsychotics cause metabolic syndrome. This aligns with DSM-5-TR criteria and
current psychopharmacology guidelines for Bipolar I & II.
7. What is the first-line pharmacologic treatment for Personality Disorders?
A. Antipsychotic first
B. No medication
C. Benzodiazepine monotherapy
D. SSRI/SNRI
Rationale: SSRIs/SNRIs are first-line for most mood and anxiety disorders due to efficacy and safety profile.
This aligns with DSM-5-TR criteria and current psychopharmacology guidelines for Personality Disorders.
8. Which psychotherapy modality is evidence-based for Substance Use Disorder?
A. Avoidance therapy
B. Cognitive Behavioral Therapy (CBT)
C. Hypnosis only
D. No therapy indicated
Rationale: CBT has strongest evidence for depression, anxiety, PTSD, OCD, and many other disorders. This
aligns with DSM-5-TR criteria and current psychopharmacology guidelines for Substance Use Disorder.
, 9. How long should a patient continue antidepressant therapy after remission of Major
Depressive Disorder?
A. 2 weeks
B. 3 days
C. 6-12 months minimum for first episode
D. Stop immediately when feeling better
Rationale: Continuation phase prevents relapse; first episode requires 6-12 months. This aligns with
DSM-5-TR criteria and current psychopharmacology guidelines for Major Depressive Disorder.
10. A patient asks about non-pharmacologic strategies for Schizophrenia, what should you
recommend?
A. Stop all meds
B. Sleep hygiene, exercise, and structured therapy
C. Isolation
D. Increased caffeine
Rationale: Lifestyle + therapy improves outcomes and medication response. This aligns with DSM-5-TR
criteria and current psychopharmacology guidelines for Schizophrenia.
11. Which psychotherapy modality is evidence-based for Psychopharmacology?
A. Avoidance therapy
B. Cognitive Behavioral Therapy (CBT)
C. Hypnosis only
D. No therapy indicated
Rationale: CBT has strongest evidence for depression, anxiety, PTSD, OCD, and many other disorders. This
aligns with DSM-5-TR criteria and current psychopharmacology guidelines for Psychopharmacology.
12. A patient asks about non-pharmacologic strategies for Generalized Anxiety Disorder, what
should you recommend?
A. Sleep hygiene, exercise, and structured therapy
B. Stop all meds
C. Increased caffeine
D. Isolation
Rationale: Lifestyle + therapy improves outcomes and medication response. This aligns with DSM-5-TR
criteria and current psychopharmacology guidelines for Generalized Anxiety Disorder.
13. What is the first-line pharmacologic treatment for Sleep Disorders?
A. SSRI/SNRI
B. No medication
C. Benzodiazepine monotherapy
D. Antipsychotic first
Rationale: SSRIs/SNRIs are first-line for most mood and anxiety disorders due to efficacy and safety profile.
This aligns with DSM-5-TR criteria and current psychopharmacology guidelines for Sleep Disorders.
REAL EXAM QUESTIONS AND 100% VERIFIED
ANSWERS + RATIONALE
Advanced Psychopharmacology & Mental Health - Comprehensive Review Edition
OVERVIEW: This 2026 practice exam is designed to mirror the structure and difficulty of
Chamberlain NR 605 Exam 3. It covers Major Depressive Disorder, Bipolar Disorders, Anxiety
Disorders, Schizophrenia Spectrum, Substance Use Disorders, Neurocognitive Disorders,
Psychopharmacology Principles, and Emergency Psychiatry.
All correct answes are highlight with green and Rationale After.
Total Questions: 138 | Time Suggestion: 3 hours | Passing Target: 100%+
1. Which adverse effect must be monitored when prescribing Lithium for
Psychopharmacology?
A. No monitoring needed
B. Increased hair growth
C. Increased creatinine and hypothyroidism
D. Weight loss only
Rationale: Lithium affects kidneys and thyroid, requires regular BMP and TSH. This aligns with DSM-5-TR
criteria and current psychopharmacology guidelines for Psychopharmacology.
2. Which adverse effect must be monitored when prescribing Sertraline for Emergency
Psychiatry?
A. Weight loss only
B. Increased hair growth
C. GI upset and SIADH/hyponatremia
D. No monitoring needed
Rationale: SSRIs can cause nausea and hyponatremia especially in elderly. This aligns with DSM-5-TR
criteria and current psychopharmacology guidelines for Emergency Psychiatry.
3. How long should a patient continue antidepressant therapy after remission of Bipolar I & II?
A. Stop immediately when feeling better
B. 3 days
C. 2 weeks
D. 6-12 months minimum for first episode
, Rationale: Continuation phase prevents relapse; first episode requires 6-12 months. This aligns with
DSM-5-TR criteria and current psychopharmacology guidelines for Bipolar I & II.
4. Which lab finding is associated with chronic use of Clozapine?
A. No labs affected
B. Decreased shoe size
C. Agranulocytosis and metabolic syndrome
D. Increased height
Rationale: Clozapine requires ANC monitoring and metabolic screening. This aligns with DSM-5-TR criteria
and current psychopharmacology guidelines for Emergency Psychiatry.
5. Which lab finding is associated with chronic use of Valproate?
A. Increased height
B. Decreased shoe size
C. Elevated LFTs and thrombocytopenia
D. No labs affected
Rationale: Valproate can cause hepatotoxicity and low platelets. This aligns with DSM-5-TR criteria and
current psychopharmacology guidelines for Emergency Psychiatry.
6. Which adverse effect must be monitored when prescribing Olanzapine for Bipolar I & II?
A. Weight gain and hyperglycemia
B. No monitoring needed
C. Weight loss only
D. Increased hair growth
Rationale: Second-gen antipsychotics cause metabolic syndrome. This aligns with DSM-5-TR criteria and
current psychopharmacology guidelines for Bipolar I & II.
7. What is the first-line pharmacologic treatment for Personality Disorders?
A. Antipsychotic first
B. No medication
C. Benzodiazepine monotherapy
D. SSRI/SNRI
Rationale: SSRIs/SNRIs are first-line for most mood and anxiety disorders due to efficacy and safety profile.
This aligns with DSM-5-TR criteria and current psychopharmacology guidelines for Personality Disorders.
8. Which psychotherapy modality is evidence-based for Substance Use Disorder?
A. Avoidance therapy
B. Cognitive Behavioral Therapy (CBT)
C. Hypnosis only
D. No therapy indicated
Rationale: CBT has strongest evidence for depression, anxiety, PTSD, OCD, and many other disorders. This
aligns with DSM-5-TR criteria and current psychopharmacology guidelines for Substance Use Disorder.
, 9. How long should a patient continue antidepressant therapy after remission of Major
Depressive Disorder?
A. 2 weeks
B. 3 days
C. 6-12 months minimum for first episode
D. Stop immediately when feeling better
Rationale: Continuation phase prevents relapse; first episode requires 6-12 months. This aligns with
DSM-5-TR criteria and current psychopharmacology guidelines for Major Depressive Disorder.
10. A patient asks about non-pharmacologic strategies for Schizophrenia, what should you
recommend?
A. Stop all meds
B. Sleep hygiene, exercise, and structured therapy
C. Isolation
D. Increased caffeine
Rationale: Lifestyle + therapy improves outcomes and medication response. This aligns with DSM-5-TR
criteria and current psychopharmacology guidelines for Schizophrenia.
11. Which psychotherapy modality is evidence-based for Psychopharmacology?
A. Avoidance therapy
B. Cognitive Behavioral Therapy (CBT)
C. Hypnosis only
D. No therapy indicated
Rationale: CBT has strongest evidence for depression, anxiety, PTSD, OCD, and many other disorders. This
aligns with DSM-5-TR criteria and current psychopharmacology guidelines for Psychopharmacology.
12. A patient asks about non-pharmacologic strategies for Generalized Anxiety Disorder, what
should you recommend?
A. Sleep hygiene, exercise, and structured therapy
B. Stop all meds
C. Increased caffeine
D. Isolation
Rationale: Lifestyle + therapy improves outcomes and medication response. This aligns with DSM-5-TR
criteria and current psychopharmacology guidelines for Generalized Anxiety Disorder.
13. What is the first-line pharmacologic treatment for Sleep Disorders?
A. SSRI/SNRI
B. No medication
C. Benzodiazepine monotherapy
D. Antipsychotic first
Rationale: SSRIs/SNRIs are first-line for most mood and anxiety disorders due to efficacy and safety profile.
This aligns with DSM-5-TR criteria and current psychopharmacology guidelines for Sleep Disorders.
